Abstract
Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system. Diseasemodifying drugs licensed for MS treatment have been developed to reduce relapse rates and halt disease progression. The majority of current MS drugs involve regular, parenteral administration, affecting long-term adherence and thus reducing treatment efficacy. Over the last two decades great progress has been made towards developing new MS therapies with different modes of action and biologic effects. In particular, oral drugs have generated much interest because of their convenience and positive impact on medication adherence. Fingolimod was the first launched oral treatment for relapsing-remitting MS; recently, Teriflunomide and Dimethyl fumarate have also been approved as oral disease-modifying agents. In this review, we summarize and discuss the history, pharmacodynamics, efficacy, and safety of oral agents that have been approved or are under development for the selective treatment of MS.
Keywords: Multiple sclerosis, oral drugs, medication adherence, efficacy, safety.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Oral Agents in Multiple Sclerosis
Volume: 14 Issue: 1
Author(s): L. Lorefice, G. Fenu, J. Frau, G.C. Coghe, M.G. Marrosu and E. Cocco
Affiliation:
Keywords: Multiple sclerosis, oral drugs, medication adherence, efficacy, safety.
Abstract: Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system. Diseasemodifying drugs licensed for MS treatment have been developed to reduce relapse rates and halt disease progression. The majority of current MS drugs involve regular, parenteral administration, affecting long-term adherence and thus reducing treatment efficacy. Over the last two decades great progress has been made towards developing new MS therapies with different modes of action and biologic effects. In particular, oral drugs have generated much interest because of their convenience and positive impact on medication adherence. Fingolimod was the first launched oral treatment for relapsing-remitting MS; recently, Teriflunomide and Dimethyl fumarate have also been approved as oral disease-modifying agents. In this review, we summarize and discuss the history, pharmacodynamics, efficacy, and safety of oral agents that have been approved or are under development for the selective treatment of MS.
Export Options
About this article
Cite this article as:
Lorefice L., Fenu G., Frau J., Coghe G.C., Marrosu M.G. and Cocco E., Oral Agents in Multiple Sclerosis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2015; 14 (1) . https://dx.doi.org/10.2174/1871523014999150415130224
DOI https://dx.doi.org/10.2174/1871523014999150415130224 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurological Involvement as the Initial Manifestation in Primary Sjögren's Syndrome - A Case Report
Current Rheumatology Reviews Antibody Penetration Into Living Cells: Pathogenic, Preventive and Immuno-Therapeutic Implications
Current Pharmaceutical Design Biochemical Markers of Renal Function
Current Medicinal Chemistry Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Pulmonary Infections in the Era of Biological Agents
Current Respiratory Medicine Reviews Directing an Appropriate Immune Response: The Role of Defense Collagens and other Soluble Pattern Recognition Molecules
Current Drug Targets Therapeutic Benefits of Regulating Inflammation in Autoimmunity
Inflammation & Allergy - Drug Targets (Discontinued) Monoclonal Antibody-based Genetic Immunotherapy
Current Gene Therapy CRP and Anti-CRP Autoantibodies in Systemic Lupus Erythematosus
Current Rheumatology Reviews Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy The Current Role and Therapeutic Targets of Vitamin D in Gastrointestinal Inflammation and Cancer
Current Pharmaceutical Design Multivalent Compounds for Antigen-Specific B Cell Tolerance and Treatment of Autoimmune Diseases
Current Medicinal Chemistry Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents
Current Medicinal Chemistry Selenium and Autoimmune Diseases: A Review Article
Current Rheumatology Reviews Systemic Lupus Erythematosus and Other Autoimmune Diseases from Endogenous and Exogenous Agents: Unifying Theme of Oxidative Stress
Mini-Reviews in Medicinal Chemistry IL-27: Friend or Foe in the Autoimmune Diseases
Current Immunology Reviews (Discontinued) Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Current Topics in Medicinal Chemistry Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances
Current Pharmaceutical Design